Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Aim: The cost-effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost-effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.
Critchlow, Simone
5399d43b-6551-49e0-9bc1-de70dc88051f
Bullement, Ash
ade71db5-e238-44ea-8ae6-520f1af7ddc4
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Jones, Robert
ccc0201e-056c-4c4e-b4af-e35a0ee0860c
Christoforou, Katerina
7cdae9da-5d5f-4be1-99f4-80a29a0cbe83
Amin, Amerah
f0328fb3-c48e-4d40-b9ba-ef1473a727df
Xiao, Ying
bfb6f5fc-1143-4743-afbf-0faa91d11e15
Kapetanakis, Venediktos
b14673c2-297c-4369-87e9-668ae07dfd6e
Benedict, Ágnes
4c61ddd5-6e79-424a-99a3-aaafd9505770
Chang, Jane
8ef9b2a8-b46e-48f4-9468-39ab631f1f98
Kearney, Mairead
55ed6a4f-c1a9-4517-855d-5e75473c4abb
Eccleston, Anthony
c02f8c79-b560-4c16-84f8-0f15e3366a25
2 August 2023
Critchlow, Simone
5399d43b-6551-49e0-9bc1-de70dc88051f
Bullement, Ash
ade71db5-e238-44ea-8ae6-520f1af7ddc4
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Jones, Robert
ccc0201e-056c-4c4e-b4af-e35a0ee0860c
Christoforou, Katerina
7cdae9da-5d5f-4be1-99f4-80a29a0cbe83
Amin, Amerah
f0328fb3-c48e-4d40-b9ba-ef1473a727df
Xiao, Ying
bfb6f5fc-1143-4743-afbf-0faa91d11e15
Kapetanakis, Venediktos
b14673c2-297c-4369-87e9-668ae07dfd6e
Benedict, Ágnes
4c61ddd5-6e79-424a-99a3-aaafd9505770
Chang, Jane
8ef9b2a8-b46e-48f4-9468-39ab631f1f98
Kearney, Mairead
55ed6a4f-c1a9-4517-855d-5e75473c4abb
Eccleston, Anthony
c02f8c79-b560-4c16-84f8-0f15e3366a25
Critchlow, Simone, Bullement, Ash, Crabb, Simon, Jones, Robert, Christoforou, Katerina, Amin, Amerah, Xiao, Ying, Kapetanakis, Venediktos, Benedict, Ágnes, Chang, Jane, Kearney, Mairead and Eccleston, Anthony
(2023)
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
Future Oncology.
(doi:10.2217/fon-2023-0372).
Abstract
Aim: The cost-effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost-effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.
Text
critchlow-et-al-2023-cost-effectiveness-analysis-for-avelumab-first-line-maintenance-treatment-of-advanced-urothelial
- Version of Record
More information
Accepted/In Press date: 14 July 2023
e-pub ahead of print date: 2 August 2023
Published date: 2 August 2023
Identifiers
Local EPrints ID: 481367
URI: http://eprints.soton.ac.uk/id/eprint/481367
ISSN: 1479-6694
PURE UUID: fca2c0b9-343e-41e5-89b7-633d6b04ddad
Catalogue record
Date deposited: 24 Aug 2023 16:36
Last modified: 18 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
Simone Critchlow
Author:
Ash Bullement
Author:
Robert Jones
Author:
Katerina Christoforou
Author:
Amerah Amin
Author:
Ying Xiao
Author:
Venediktos Kapetanakis
Author:
Ágnes Benedict
Author:
Jane Chang
Author:
Mairead Kearney
Author:
Anthony Eccleston
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
